Q32 Bio Inc.

$5.67-6.59%($-0.40)
TickerSpark Score
79/100
Solid
93
Valuation
100
Profitability
60
Growth
84
Health
60
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QTTB research report →

52-Week Range65% of range
Low $1.34
Current $5.67
High $8.04

Companywww.q32bio.com

Q32 Bio Inc. , a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.

CEO
Jodie Pope Morrison
IPO
2018
Employees
28
HQ
Waltham, MA, US

Price Chart

+220.34% · this period
$7.30$4.33$1.36May 20Nov 18May 20

Valuation

Market Cap
$72.44M
P/E
2.40
P/S
1.35
P/B
1.73
EV/EBITDA
1.48
Div Yield
0.00%

Profitability

Gross Margin
99.50%
Op Margin
39.84%
Net Margin
61.86%
ROE
230.68%
ROIC
36.14%

Growth & Income

Revenue
$53.74M · 0.00%
Net Income
$29.82M · 162.47%
EPS
$2.42 · 147.27%
Op Income
$16.90M
FCF YoY
50.52%

Performance & Tape

52W High
$8.04
52W Low
$1.34
50D MA
$6.05
200D MA
$3.71
Beta
-1.27
Avg Volume
305.93K

Get TickerSpark's AI analysis on QTTB

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Feb 24, 26Violette Shelia M.other37,500
Feb 24, 26Morrison Jodie Popeother132,000
Feb 24, 26Kalowski Leeother53,250
Feb 25, 26Kalowski Leesell3,995
Feb 25, 26Morrison Jodie Popesell9,896
Feb 25, 26Violette Shelia M.sell2,815
Jan 15, 26LAPORTE KATHLEENother23,272
Jan 15, 26GRAYZEL DAVID S.other16,363
Jan 15, 26Lundberg Sven Anteother20,363
Dec 2, 25Morrison Jodie Popesell22,506

Our QTTB Coverage

We haven't published any research on QTTB yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate QTTB Report →

Similar Companies